Boehringer Ingelheim International GmbH — Sponsor Intelligence | 166 EU Trials

Filter these 166 trials by condition, phase, country and more.

Open in Search →

166 Registered trials

39 Recruiting

133 Completed trials

25 Countries active

57 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 24 Phase II/III: 4 Phase II: 23 Phase I/II: 3 Phase III/IV: 1 Phase I: 21 Phase I (Other): 84 Phase I (FiH): 1 Other: 5

Oversight events:

6 serious breaches 86 temporary halts 3 corrective measures across 24 trials

View oversight register →

100%

133 of 133 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Obesity 4 Neuroendocrine carcinoma 2 Bronchiectasis 2 Non-small cell lung cancer 2 Portal hypertension 2 Small cell lung cancer extensive stage 2 Cystic fibrosis lung 2 Glioma 1 Pancreatic carcinoma 1 Small cell lung cancer 1 Acute myocardial infarction 1 Cystic fibrosis 1

Top IMPs

BI 1015550 6 SPESOLIMAB 6 1-[[(5R)-2-[4-(5-CHLORO-2-PYRIMIDINYL)-1-PIPERIDINYL]-6,7- DIHYDRO-5-OXIDOTHIENO[3,2-D]PYRIMIDIN-4- YL]AMINO]-CYCLOBUTANEMETHANOL 5 ZONGERTINIB 5 (3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)-6'-METHYL-2-OXO-1,2,3',3A',10',10A'-HEXAHYDRO-1'H-SPIRO[INDOLE-3,2'-PYRROLO[2',3':4,5]PYRROLO[1,2-B]INDAZOLE]-7'-CARBOXYLIC ACID 4 [4-(6-AMINOPYRIDAZIN-3-YL)PIPERIDIN-1-YL][5-(4-FLUOROPHENOXY)-4-METHOXYPYRIDIN-2-YL]METHANONE 4 BI 1291583 4 BI 456906 4 BI 690517 4 CARBOPLATIN 4 SURVODUTIDE 4 BI 685509 3

All trials

166 total

A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced… Pending

2025-521438-27-00 Phase I 4 countries
A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps Pending

2025-522045-21-00 Phase I 2 countries
A study to find out how nerandomilast is tolerated, handled by the body, and if it helps children and adolescents with interstitial lung dis… Pending

2025-523369-32-00 Phase III 5 countries 1-[[(5R)-2-[4-(5-CHLORO-2-PYRIMIDINYL)-1-PIPERIDINYL]-6,7- DIHYDRO-5-OXIDOTHIENO…
A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta… Pending

2025-523869-22-00 Phase III 14 countries CARBOPLATIN; ETOPOSIDE; IGG-LIKE T CELL ENGAGER BINDING TO DLL3 AND CD3; TOCILIZ…
A study in healthy men to test how BI 1815368 is processed in the body Pending

2025-523949-10-00 Phase I (Other) 1 country
A study in healthy people or otherwise healthy but overweight or obese to compare 2 formulations of survodutide given in different ways, eit… Pending

2025-524135-39-00 Phase I (Other) 1 country
A study in healthy men to find out how blocking certain transport proteins affects the amount of BI 3000202 in the blood Pending

2026-525549-60-00 Phase I (Other) 1 country
A study in healthy people to compare two tablet formulations of pramipexole Pending

2026-525704-98-00 1 country
DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t… Recruiting

2025-520565-51-00 Phase III 20 countries ATEZOLIZUMAB; CARBOPLATIN; ETOPOSIDE; IGG-LIKE T CELL ENGAGER BINDING TO DLL3 AN…
PODOMOUNT-Basket, a study to test whether BI 764198 helps adults and adolescents with different types of kidney disease Recruiting

2025-523425-17-00 Phase II 16 countries [4-(6-AMINOPYRIDAZIN-3-YL)PIPERIDIN-1-YL][5-(4-FLUOROPHENOXY)-4-METHOXYPYRIDIN-2…
A study to test whether different doses of BI 3000202 help people with systemic lupus erythematosus (SLE) Recruiting

2025-523488-39-00 Phase II 7 countries BI 3000202
Beamion 44: A study to test how well zongertinib is tolerated by people with advanced non-small cell lung cancer with HER2 mutations when gi… Recruiting

2025-523567-38-00 Phase II 3 countries CARBOPLATIN; CISPLATIN; PEMBROLIZUMAB; PEMETREXED; ZONGERTINIB
A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting

2025-522191-86-00 Phase III 15 countries [4-(6-AMINOPYRIDAZIN-3-YL)PIPERIDIN-1-YL][5-(4-FLUOROPHENOXY)-4-METHOXYPYRIDIN-2…
The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting

2024-518589-29-00 Phase III 22 countries BI 1291583
KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer Recruiting

2022-501854-12-01 Phase I 3 countries
Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps … Recruiting

2023-509566-38-00 Phase I/II 5 countries CALCIUM FOLINATE; CAPECITABINE; FLUOROURACIL; OXALIPLATIN; TRASTUZUMAB; TRASTUZU…
A study to test whether survodutide helps people living with obesity or overweight and with a confirmed or presumed liver disease called non… Recruiting

2023-505303-23-00 Phase III 3 countries BI 456906; SURVODUTIDE
BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c… Recruiting

2023-504308-27-00 Phase III 13 countries CARBOPLATIN; CISPLATIN; PEMBROLIZUMAB; PEMETREXED; ZONGERTINIB
A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting

2023-504247-13-00 Phase II 8 countries BI 764532; IGG-LIKE T CELL ENGAGER BINDING TO DLL3 AND CD3
Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this … Recruiting

2023-503290-38-00 Phase II 14 countries BI 1291583
A study to test if tenecteplase helps people to recover from an acute stroke when given more than 4.5 hours after the person was last seen w… Recruiting

2025-522542-40-00 Phase III 6 countries TENECTEPLASE
A study in healthy men to test how bosentan influences the amount of zongertinib in the blood Recruiting

2025-523193-16-00 Phase I (Other) 1 country
A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours) Recruiting

2025-522913-45-00 Phase I (Other) 4 countries
A study to test how different doses of BI 3814916 are tolerated by healthy people Recruiting

2025-523262-25-00 Phase I 1 country

Showing 1–24 of 166 trials

← All sponsors A–Z